ArticleJournal of fluorescence2025
Novel Silicon-Based Fluorescent Nanocomposite Drug Carriers for Natural Compound Delivery in Melanoma Treatment.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma, a highly aggressive cancer, is closely associated with an elevated tumor mutation burden (TMB) and an active tumor microenvironment (TME). Melanin synthesis, a key feature of melanoma progression, is primarily regulated by tyrosinase (TYR), the rate-limiting enzyme controlled by the microphthalmia-associated transcription factor (MITF). Resveratrol (Res), a natural polyphenol known for its antioxidant and anticancer properties, faces limitations including poor solubility, low bioavailability, and rapid metabolism. To overcome these challenges, a three-dimensional Co(II) coordination polymer {[Co(bpdado)(bpe)(H₂O)₂]·2DMF·2 H₂O}n (1) was synthesized and incorporated into a composite material, 1@CP1, for Res delivery (1@CP1@Res). The system exhibited enhanced solubility, pH-sensitive release, and improved biological activity. Fluorescence assays demonstrated significant quenching in the presence of Cu²⁺ ions, indicating a high sensitivity of 1@CP1@Res to metal ion interactions. The pH-responsive drug release profile was confirmed by in vitro studies showing accelerated release at lower pH values, mimicking the acidic tumor microenvironment. Cell viability assays revealed that 1@CP1@Res significantly inhibited the proliferation of murine B16-F10 melanoma cells, with cell survival rates of 72.4%, 58.2%, and 43.6% at 24, 48, and 72 h of incubation, respectively, at a concentration of 100 µM. Molecular docking studies further revealed multiple binding interactions between Res and the coordination polymer, suggesting a promising therapeutic strategy for melanoma treatment by integrating advanced materials with bioactive compounds.
Indexed as
Identifiers
39992321What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.